NCT05610657View on ClinicalTrials.gov

A Pharmacokinetic Study of Mitapivat in Participants With Moderate Hepatic Impairment Compared to Matched Healthy Control Participants With Normal Hepatic Function

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 10, 2023

Primary Completion Date

July 21, 2023

Study Completion Date

July 21, 2023

Conditions
Moderate Hepatic Impairment
Interventions
DRUG

Mitapivat

Mitapivat tablets

Trial Locations (3)

32809

Orlando Clinical Research Center (OCRC), Orlando

33014

Clinical Pharmacology of Miami (CPMI), Miami

92780

Orange County Research Center (OCRC), Tustin

Sponsors
All Listed Sponsors
lead

Agios Pharmaceuticals, Inc.

INDUSTRY